Unlike rituximab (anti-CD20), which spares tissue-resident and memory B cells, CD19-CAR T cells deplete both peripheral and tissue B cells, a critical feature in diseases such as RA, systemic lupus erythematosus, and systemic sclerosis [69]. Here, CD19 is linked to rheumatoid arthritis.